XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1
FAIR VALUE DISCLOSURES (Tables)
6 Months Ended
Jun. 30, 2024
Fair Value Disclosures [Abstract]  
Schedule of recurring Level 3 fair value measurements of contingent consideration
The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs as of June 30, 2024:
Payment TypeValuation TechniqueUnobservable InputAssumptions
Profit-based milestone paymentsProbability-weighted discounted cash flowDiscount rate13%
Projected fiscal year of payment2025-2035
Schedule of changes in contingent consideration
The following table presents the changes in contingent consideration balances classified as Level 3 for the three and six months ended June 30, 2024 and 2023:
Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2024202320242023
Beginning balance$11,574 $36,019 $23,984 $35,058 
Payment of Gross-Profit earn-out— — (12,500)— 
Change in fair value359 1,035 449 1,996 
Ending balance$11,933 $37,054 $11,933 $37,054 
Schedule of financial assets and liabilities accounted for at fair value on a recurring basis
The following table presents our financial assets and liabilities accounted for at fair value on a recurring basis as of June 30, 2024 and December 31, 2023, by level within the fair value hierarchy:
(in thousands)
Description
Fair Value at
June 30, 2024
Level 1Level 2Level 3
Assets
Money Market Fund$166,485 $166,485 $— $— 
Interest rate swap$7,366 $— $7,366 $— 
  CG Oncology - Investment in equity securities$6,943 $6,943 $— $— 
Liabilities    
Contingent consideration$11,933 $— $— $11,933 
DescriptionFair Value at
December 31, 2023
Level 1Level 2Level 3
Assets   
Money Market Fund$191,841 $191,841 $— $— 
Interest rate swap$6,236 $— $6,236 $— 
Liabilities    
Contingent consideration$23,984 $— $— $23,984